H-ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR-OH manufacturers
|
| | H-ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR-OH Basic information |
| Product Name: | H-ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR-OH | | Synonyms: | AQDFVQWLMNT;H-ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR-OH;GLUCAGON (19-29), BOVINE, HUMAN, PORCINE;GLUCAGON (19-29) (HUMAN, BOVINE, PORCINE);ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR;glucagon(19-29;PHE-VAL-GLN-TRP-LEU-MET-ASN-THR: FVQWLMNT;Glucagon (19-29) (human, rat, porcine) | | CAS: | 64790-15-4 | | MF: | C61H89N15O18S | | MW: | 1352.51 | | EINECS: | | | Product Categories: | Peptide;Obesity | | Mol File: | 64790-15-4.mol |  |
| | H-ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR-OH Chemical Properties |
| Boiling point | 1828.5±65.0 °C(Predicted) | | density | 1.339±0.06 g/cm3(Predicted) | | storage temp. | -15°C | | solubility | insoluble in EtOH; insoluble in H2O; ≥135.2 mg/mL in DMSO | | pka | 3.19±0.10(Predicted) | | form | Powder | | color | White to off-white | | Sequence | Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr |
| | H-ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR-OH Usage And Synthesis |
| Uses | This fragment inhibits calcium activated ATPase activity | | in vivo | Glucagon (19-29), also named Miniglucagon, is the COOH-terminal (19-29) fragment processed from glucagon. Glucagon (19-29) dose-dependently inhibits insulin secretion stimulated by 8.3 M glucose, with no change in the perfusion flow rate. A concentration of 1 nM Glucagon (19-29) has a significant inhibitory effect on a 1 nM glucagon-like peptide 1 (7-36) amide–potentiated insulin secretion[1]. Glucagon (19-29) is a highly potent and efficient inhibitor of insulin release by closing, via hyperpolarization, voltage-dependent Ca2+ channels linked to a pathway involving a pertussis toxin-sensitive G protein[2]. |
| | H-ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR-OH Preparation Products And Raw materials |
|